Pfizer Inc. (NYSE:PFE) Shares Acquired by Berkeley Capital Partners LLC

Berkeley Capital Partners LLC increased its stake in Pfizer Inc. (NYSE:PFE) by 2.3% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 69,190 shares of the biopharmaceutical company’s stock after acquiring an additional 1,531 shares during the quarter. Berkeley Capital Partners LLC’s holdings in Pfizer were worth $1,836,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the stock. State Street Corp grew its holdings in shares of Pfizer by 1.2% in the 3rd quarter. State Street Corp now owns 290,460,600 shares of the biopharmaceutical company’s stock worth $8,405,930,000 after acquiring an additional 3,405,539 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of Pfizer by 19.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company’s stock worth $4,124,330,000 after buying an additional 25,315,159 shares during the period. Geode Capital Management LLC boosted its position in shares of Pfizer by 1.6% in the third quarter. Geode Capital Management LLC now owns 117,666,245 shares of the biopharmaceutical company’s stock worth $3,392,342,000 after buying an additional 1,855,419 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Pfizer by 22.4% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 38,068,879 shares of the biopharmaceutical company’s stock worth $1,101,713,000 after buying an additional 6,977,587 shares during the period. Finally, Van ECK Associates Corp boosted its position in shares of Pfizer by 28.5% in the fourth quarter. Van ECK Associates Corp now owns 21,286,805 shares of the biopharmaceutical company’s stock worth $564,739,000 after buying an additional 4,726,549 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Price Performance

Shares of NYSE:PFE opened at $26.18 on Thursday. Pfizer Inc. has a fifty-two week low of $24.48 and a fifty-two week high of $31.54. The business has a 50-day moving average of $26.19 and a two-hundred day moving average of $27.08. The stock has a market capitalization of $148.35 billion, a P/E ratio of 18.57, a P/E/G ratio of 0.64 and a beta of 0.61. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. The company had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business’s quarterly revenue was up 24.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.10 earnings per share. On average, equities research analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Analyst Ratings Changes

PFE has been the subject of several recent analyst reports. Bank of America reaffirmed a “neutral” rating and issued a $29.00 target price on shares of Pfizer in a research report on Tuesday, December 10th. UBS Group decreased their target price on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a research report on Tuesday. Truist Financial decreased their target price on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. Finally, Citigroup decreased their target price on Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $31.92.

Insider Transactions at Pfizer

In other Pfizer news, Director Ronald E. Blaylock acquired 19,457 shares of the company’s stock in a transaction dated Thursday, February 13th. The shares were acquired at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the purchase, the director now owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. 0.06% of the stock is currently owned by corporate insiders.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.